Piracetam Effects on Myelination Deficiency

We assessed whether or not Piracetam could improve the phenotype of a naturally occurring Plp1^A243V mouse model, myelin synthesis deficiency (msd) mouse”. We treated wild-type and msd mice with Piracetam and vehicle to examine the effect of Piracetam on body weight and survival. All msd mice were male. Piracetam (CAS No. 7491-74-9) was purchased from Sigma-Aldrich Co., LLC (St. Louis, MO, USA). For the treated group (N = 14), 200 mg/kg of Piracetam dissolved in PBS (final concentration of Piracetam: 60 mg/ml) was administered by intraperitoneal injection for 5 consecutive days per week from postnatal day 3. For the control group (N = 24), the same amount of PBS was administered in the same pattern. The dosage of Piracetam was determined by referencing previous reports [[28] (link), [29] (link), [30] (link)]. All of the animal handling and treatment protocols were reviewed and approved by the Animal Care and Use Committee of National Institute of Neuroscience, National Center of Neurology and Psychiatry (approval number, 2017010).